Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY):a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial (vol 397, pg 475, 2021)

被引：0
|
作者：
Gordon, K. B.
Foley, P.
Krueger, J. G.
机构：
来源：
LANCET | 2021年 / 397卷 / 10280期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1182 / 1182
页数：1
相关论文
共 50 条
  • [1] Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
    Gordon, Kenneth B.
    Foley, Peter
    Krueger, James G.
    Pinter, Andreas
    Reich, Kristian
    Vender, Ronald
    Vanvoorden, Veerle
    Madden, Cynthia
    White, Katy
    Cioffi, Christopher
    Blauvelt, Andrew
    [J]. LANCET, 2021, 397 (10273): : 475 - 486
  • [2] Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial (vol 397, pg 487, 2021)
    Reich, K.
    Papp, K. A.
    Blauvelt, A.
    [J]. LANCET, 2021, 397 (10275): : 670 - 670
  • [3] Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial (vol 397, pg 2070, 2021)
    Rovin, B. H.
    Teng, Y. K. O.
    Ginzler, E. M.
    [J]. LANCET, 2021, 397 (10289): : 2048 - 2048
  • [4] Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial (vol 157, pg 1279, 2021)
    Terlizzi, Joseph P.
    Baker, Jonathan
    Goldstone, Stephen E.
    [J]. JAMA DERMATOLOGY, 2021, 157 (11) : 1384 - 1384
  • [5] Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial
    Glatt, Sophie
    Jemec, Gregor B. E.
    Forman, Seth
    Sayed, Christopher
    Schmieder, George
    Weisman, Jamie
    Rolleri, Robert
    Seegobin, Seth
    Baeten, Dominique
    Ionescu, Lucian
    Zouboulis, Christos C.
    Shaw, Stevan
    [J]. JAMA DERMATOLOGY, 2021, 157 (11) : 1279 - 1288
  • [6] Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
    Reich, Kristian
    Papp, Kim A.
    Blauvelt, Andrew
    Langley, Richard G.
    Armstrong, April
    Warren, Richard B.
    Gordon, Kenneth B.
    Merola, Joseph F.
    Okubo, Yukari
    Madden, Cynthia
    Wang, Maggie
    Cioffi, Christopher
    Vanvoorden, Veerle
    Lebwohl, Mark
    [J]. LANCET, 2021, 397 (10273): : 487 - 498
  • [7] Efficacy and safety of total glucosides of paeony combined with acitretin in the treatment of moderate-to-severe plaque psoriasis: a double-blind, randomised, placebo-controlled trial
    Chen Yu
    Xueli Fan
    Zhenlu Li
    Xiaoming Liu
    Gang Wang
    [J]. European Journal of Dermatology, 2017, 27 : 150 - 154
  • [8] Efficacy and safety of total glucosides of paeony combined with acitretin in the treatment of moderate-to-severe plaque psoriasis: a double-blind, randomised, placebo-controlled trial
    Yu, Chen
    Fan, Xueli
    Li, Zhenlu
    Liu, Xiaoming
    Wang, Gangwang
    [J]. EUROPEAN JOURNAL OF DERMATOLOGY, 2017, 27 (02) : 150 - 154
  • [9] Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo-controlled, double-blinded study
    Youn, Sang Woong
    Jo, Seong Jin
    Park, Chul Jong
    Kim, Dong Hyun
    Shin, Bong Seok
    Jeong, Ki Heon
    Bang, Chul Hwan
    Cross, Nancy
    Thirlwell, Jackie
    Hoepken, Bengt
    [J]. JOURNAL OF DERMATOLOGY, 2024,
  • [10] Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study
    Papp, K.
    Bissonnette, R.
    Rosoph, L.
    Wasel, N.
    Lynde, C. W.
    Searles, G.
    Shear, N. H.
    Huizinga, R. B.
    Maksymowych, W. P.
    [J]. LANCET, 2008, 371 (9621): : 1337 - 1342
12345